Typhoid conjugate vaccine introduction cost to countries and support from Gavi, the Vaccine Alliance

The World Health Organization recommends TCV introduction for infants and children over 6 months of age as a single dose, and where feasible, a single dose catch-up of children up to 15 years of age.

	CAMPAIGN			ROUTINE IMMUNIZATION				
TARGET POPULATION	Up to 15 years old			Infants & children older than 6 months ¹				
VACCINE PRICE PER DOSE ²	\$1.39			\$1.39				
COST TO COUNTRY ³								
VACCINE PRICE PER DOSE TO THE COUNTRY	\$ 0 Procurement of vaccines and immunization supplies fully supported by Gavi			Co-financing based on transition phase				
				Initial self-financing	Preparato transitio		i uni	ing
				\$0.20	Based o country specific pr fractior	countrice specific p	y \$1.39	9
PAID BY GAVI								
PROGRAMMATIC SUPPORT FROM GAVI	Operational support for campaigns (Ops) Dependent on country transition phase			Vaccine Introduction Grant (wVIG) Dependent on country transition phase				
	Initial self-financing	Preparatory transition	Accelerated transition	Initial self-financin	9	Preparatory transition	Accelerated transition	
	\$0.65 per targeted person	\$0.55 per targeted person	\$0.45 per targeted person	\$0.80 per infant in the beachort in year of introduction, or a sum of US\$100,0 whichever is high	of c ump intro 100, sur	\$0.70 infant in the birth ohort in year of duction, or a lump n of US\$100,000, ichever is higher	\$0.60 per infant in the bir cohort in year of introduction, or a lui sum of US\$100,00 whichever is highe	f ump 00,

Gavi encourages countries to integrate TCV into routine immunization schedules based on the WHO recommendation and national guidelines. Older children may be vaccinated during a routine immunization if earlier vaccination is missed.

All costs are in US dollars.





² Price per dose is based on the Gavi-supported 5-dose vial presentation and is a weighted average price of the currently available TCV products.

³ Financing for syringes and safety boxes follows the same cost formula as the vaccine.

During accelerated transition, the co-financing requirement increases each year during the 8 year transition period.